Literature DB >> 27899526

Dynamic pre-BCR homodimers fine-tune autonomous survival signals in B cell precursor acute lymphoblastic leukemia.

M Frank Erasmus1,2, Ksenia Matlawska-Wasowska2,3, Ichiko Kinjyo1,2, Avanika Mahajan1,2, Stuart S Winter2,3, Li Xu4, Michael Horowitz4, Diane S Lidke1,2, Bridget S Wilson5,2.   

Abstract

The pre-B cell receptor (pre-BCR) is an immature form of the BCR critical for early B lymphocyte development. It is composed of the membrane-bound immunoglobulin (Ig) heavy chain, surrogate light chain components, and the signaling subunits Igα and Igβ. We developed monovalent quantum dot (QD)-labeled probes specific for Igβ to study the behavior of pre-BCRs engaged in autonomous, ligand-independent signaling in live B cells. Single-particle tracking revealed that QD-labeled pre-BCRs engaged in transient, but frequent, homotypic interactions. Receptor motion was correlated at short separation distances, consistent with the formation of dimers and higher-order oligomers. Repeated encounters between diffusing pre-BCRs appeared to reflect transient co-confinement in plasma membrane domains. In human B cell precursor acute lymphoblastic leukemia (BCP-ALL) cells, we showed that frequent, short-lived, homotypic pre-BCR interactions stimulated survival signals, including expression of BCL6, which encodes a transcriptional repressor. These survival signals were blocked by inhibitory monovalent antigen-binding antibody fragments (Fabs) specific for the surrogate light chain components of the pre-BCR or by inhibitors of the tyrosine kinases Lyn and Syk. For comparison, we evaluated pre-BCR aggregation mediated by dimeric galectin-1, which has binding sites for carbohydrate and for the surrogate light chain λ5 component. Galectin-1 binding resulted in the formation of large, highly immobile pre-BCR aggregates, which was partially relieved by the addition of lactose to prevent the cross-linking of galectin-BCR complexes to other glycosylated membrane components. Analysis of the pre-BCR and its signaling partners suggested that they could be potential targets for combination therapy in BCP-ALL.
Copyright © 2016, American Association for the Advancement of Science.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27899526      PMCID: PMC5385842          DOI: 10.1126/scisignal.aaf3949

Source DB:  PubMed          Journal:  Sci Signal        ISSN: 1945-0877            Impact factor:   8.192


  96 in total

1.  The nonimmunoglobulin portion of lambda5 mediates cell-autonomous pre-B cell receptor signaling.

Authors:  Kazuo Ohnishi; Fritz Melchers
Journal:  Nat Immunol       Date:  2003-08-03       Impact factor: 25.606

2.  Pre-B cell receptor assesses the quality of IgH chains and tunes the pre-B cell repertoire by delivering differential signals.

Authors:  Yohei Kawano; Soichiro Yoshikawa; Yoshiyuki Minegishi; Hajime Karasuyama
Journal:  J Immunol       Date:  2006-08-15       Impact factor: 5.422

3.  Autoreactive B cell receptors mimic autonomous pre-B cell receptor signaling and induce proliferation of early B cells.

Authors:  Fabian Köhler; Eva Hug; Cathrin Eschbach; Sonja Meixlsperger; Elias Hobeika; Juliane Kofer; Hedda Wardemann; Hassan Jumaa
Journal:  Immunity       Date:  2008-12-11       Impact factor: 31.745

4.  B-cell receptor signaling in chronic lymphocytic leukemia.

Authors:  Freda K Stevenson; Sergey Krysov; Andrew J Davies; Andrew J Steele; Graham Packham
Journal:  Blood       Date:  2011-08-03       Impact factor: 22.113

5.  Absence of surrogate light chain results in spontaneous autoreactive germinal centres expanding V(H)81X-expressing B cells.

Authors:  Ola Grimsholm; Weicheng Ren; Angelina I Bernardi; Haixia Chen; Giljun Park; Alessandro Camponeschi; Dongfeng Chen; Berglind Bergmann; Nina Höök; Sofia Andersson; Anneli Strömberg; Inger Gjertsson; Susanna Cardell; Ulf Yrlid; Alessandra De Riva; Inga-Lill Mårtensson
Journal:  Nat Commun       Date:  2015-05-11       Impact factor: 14.919

6.  N-linked glycosylation selectively regulates autonomous precursor BCR function.

Authors:  Rudolf Ubelhart; Martina P Bach; Cathrin Eschbach; Thomas Wossning; Michael Reth; Hassan Jumaa
Journal:  Nat Immunol       Date:  2010-07-11       Impact factor: 25.606

7.  Therapeutic potential of spleen tyrosine kinase inhibition for treating high-risk precursor B cell acute lymphoblastic leukemia.

Authors:  Tatiana Perova; Ildiko Grandal; Lauryl M J Nutter; Eniko Papp; Irina R Matei; Joseph Beyene; Paul E Kowalski; Johann K Hitzler; Mark D Minden; Cynthia J Guidos; Jayne S Danska
Journal:  Sci Transl Med       Date:  2014-05-14       Impact factor: 17.956

Review 8.  Syk and pTyr'd: Signaling through the B cell antigen receptor.

Authors:  Robert L Geahlen
Journal:  Biochim Biophys Acta       Date:  2009-03-21

9.  Galectin-1-expressing stromal cells constitute a specific niche for pre-BII cell development in mouse bone marrow.

Authors:  Frédéric Mourcin; Caroline Breton; Julie Tellier; Priyanka Narang; Lionel Chasson; Audrey Jorquera; Mark Coles; Claudine Schiff; Stéphane J C Mancini
Journal:  Blood       Date:  2011-04-21       Impact factor: 22.113

10.  JAK kinase inhibitors for the treatment of acute lymphoblastic leukemia.

Authors:  Sandrine Degryse; Jan Cools
Journal:  J Hematol Oncol       Date:  2015-07-26       Impact factor: 17.388

View more
  7 in total

Review 1.  Picket-fences in the plasma membrane: functions in immune cells and phagocytosis.

Authors:  Sivakami M Mylvaganam; Sergio Grinstein; Spencer A Freeman
Journal:  Semin Immunopathol       Date:  2018-09-12       Impact factor: 9.623

Review 2.  Autoimmunity checkpoints as therapeutic targets in B cell malignancies.

Authors:  Markus Müschen
Journal:  Nat Rev Cancer       Date:  2018-01-05       Impact factor: 60.716

3.  Oncogene-independent BCR-like signaling adaptation confers drug resistance in Ph-like ALL.

Authors:  Christian Hurtz; Gerald B Wertheim; Joseph P Loftus; Daniel Blumenthal; Anne Lehman; Yong Li; Asen Bagashev; Bryan Manning; Katherine D Cummins; Janis K Burkhardt; Alexander E Perl; Martin Carroll; Sarah K Tasian
Journal:  J Clin Invest       Date:  2020-07-01       Impact factor: 14.808

Review 4.  Galectin-Glycan Interactions as Regulators of B Cell Immunity.

Authors:  Nicholas Giovannone; Logan K Smith; Bebhinn Treanor; Charles J Dimitroff
Journal:  Front Immunol       Date:  2018-12-04       Impact factor: 7.561

5.  VpreB surrogate light chain expression in B-lineage ALL: a report from the Children's Oncology Group.

Authors:  Stuart S Winter; Amanda McCaustland; Chunxu Qu; No'eau Simeona; Nyla A Heerema; Andrew J Carroll; Brent L Wood; Gabriela Gheorghe; Charles G Mullighan; Bridget S Wilson
Journal:  Blood Adv       Date:  2022-01-25

6.  EGFR transactivates RON to drive oncogenic crosstalk.

Authors:  Carolina Franco Nitta; Ellen W Green; Elton D Jhamba; Justine M Keth; Iraís Ortiz-Caraveo; Rachel M Grattan; David J Schodt; Aubrey C Gibson; Ashwani Rajput; Keith A Lidke; Bridget S Wilson; Mara P Steinkamp; Diane S Lidke
Journal:  Elife       Date:  2021-11-25       Impact factor: 8.140

7.  Limitations of Qdot labelling compared to directly-conjugated probes for single particle tracking of B cell receptor mobility.

Authors:  Libin Abraham; Henry Y Lu; Rebeca Cardim Falcão; Joshua Scurll; Timothy Jou; Brian Irwin; Reza Tafteh; Michael R Gold; Daniel Coombs
Journal:  Sci Rep       Date:  2017-09-12       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.